)
Edge26 Jun 2026
The Universal Language: Inventing the Barcode
How lines in the sand on a Miami beach became the most scanned symbol in human history, and why it took decades for anyone to care.
Biovica International
Biovica International (BIOVIC) investor relations material
Biovica International Q4 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 25/26 earnings summary17 Jun, 2026
Executive summary
Achieved strong growth in Q4 and full year, with net sales up 107% in Q4 and 55% for the year compared to prior periods.
Expanded clinical evidence for DiviTum TKa, especially in metastatic breast cancer and immunotherapy settings.
Transitioned to a new CEO, Theis Kipling, effective May 2026, with a focus on commercial efficiency and financial discipline.
Initiated a strategic shift to prioritize US and Pharma Services markets, terminating EU distribution contracts.
Financial highlights
Q4 net sales: SEK 4,815k (up 107% YoY); full year net sales: SEK 13,380k (up 55% YoY).
Q4 operating loss: SEK -18,043k; full year operating loss: SEK -70,119k (improved from -85,839k YoY).
Cash and cash equivalents at year-end: SEK 70,412k (up from SEK 24,415k YoY).
Cash flow from operating activities: SEK -62,807k for the year (improved from -85,367k YoY).
Equity ratio improved to 80% from 67% YoY.
Outlook and guidance
Focus on accelerating adoption of DiviTum TKa, expanding US market presence, and deepening Pharma Services partnerships.
Emphasis on financial discipline, cost control, and resource allocation to high-value opportunities.
Board assesses sufficient liquidity for at least the next 12 months based on current forecasts.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biovica International
- Sales doubled and partnerships expanded, but liquidity risk persists despite improved cash flow.BIOVIC
Q3 24/2527 May 2026 - Major U.S. contracts and clinical data drive growth, but sales and funding risks persist.BIOVICQ2 24/2527 May 2026
- Q4 sales soared 225% YoY, with US momentum, cost cuts, and funding supporting 2025 targets.BIOVICQ4 23/2427 May 2026
- Q3 net sales up 46% year-over-year, with strong U.S. momentum and improved cash position.BIOVICQ3 25/2620 Mar 2026
- Q2 sales up 16% YoY, SEK 122.3m raised, and cash flow positivity targeted for 2027.BIOVICQ2 25/2626 Jan 2026
- US sales up 48–50%, cash flow improved, but next year's funding depends on warrants.BIOVICQ1 24/2520 Jan 2026
- US IVD sales up 72% year-over-year, SEK 122M raised, and growth momentum continues.BIOVICQ1 25/2617 Dec 2025
- US sales up 120% in Q4, major partnerships, and SEK 80M rights issue to fund expansion.BIOVICQ4 24/2514 Nov 2025
Next Biovica International earnings date
Q1 26/2710 Sep, 2026
Biovica International
Next Biovica International earnings date
Q1 26/2710 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage